[1]
|
C. L. Lai, V. Ratziu and M. F. Yuen, T Poynard, “Viral Hepatitis B,” Lancet, Vol. 362, 2003, pp. 2089-2094.
|
[2]
|
R. P. Perrillo, “Acute Flares in Chronic Hepatitis B: The Natural and Unnatural History of an Immunologically Mediated Liver Disease,” Gastroenterology, Vol. 120, No. 4, 2001, pp. 1009-1022.
|
[3]
|
G. Rossi, A. Pelizzari, M. Motta and M. Puoti, “Primary Prophylaxis with Lamivudine of Hepatitis B Virus Reactivation in Chronic HbsAg Carriers with Lymphoid Malignancies Treated with Chemotherapy,” British Journal of Haematology, Vol. 115, No. 1, 2001, pp. 58-62.
|
[4]
|
M. Mondelli, G. M. Vergani, A. Alberti, et al., “Specificity of T Lymphocyte Cytotoxicity to Autologous Hepatocytes in Chronic Hepatitis B Virus Infection: Evidence That T Cells Are Directed against HBV Core Antigen Expressed on Hepatocytes,” The Journal of Immunology, Vol. 129, No. 6, 1982, pp. 2773-2778.
|
[5]
|
S. J. Leaw, C. J. Yen, W. T. Huang, T. Y. Chen and W. C. Su, C. J. Tsao, “Preemptive Use of Interferon or Lamivudine for Hepatitis B Reactivation in Patients with Aggressive Lymphoma Receiving Chemotherapy,” Annals of Hematology, Vol. 83, No. 5, 2004, pp. 270-275.
|
[6]
|
C. Blanpain, C. Knoop, M. L. Delforge, et al., “Reactivation of Hepatitis B after Transplantation in Patients with Pre-Existing Anti-Hepatitis B Surface Antigen Antibodies,” Transplantation, Vol. 66, No. 7, 1998, pp. 883-886.
|
[7]
|
I. Cacciola, T. Pollicino, G. Squadrito, et al., “Occult hepatitis B Virus Infection in Patients with Chronic Hepatitis C Liver Disease,” The New England Journal of Medicine, Vol. 341, No. 1, 1999, pp. 22-26.
|
[8]
|
W. Yeo, P. K. S Chan, S. Zhong, et al., “Frequency of Hepatitis B Virus Reactivation in Cancer Patients Undergoing Cytotoxic Chemotherapy: A prospective Study of 626 Patients with Identification of Risk Factors,” Journal of Medicine Virology, Vol. 62, No. 3, 2000, pp. 299- 307.
|
[9]
|
A. S. F. Lok, R. H. S. Liang, E. K. W. Chiu, et al., “Reactivation of Hepatitis B Virus Replication in Patients Receiving Cytotoxic Therapy. Report of a Prospective Study,” Gastroenterology, Vol. 100, No. 1, 1991, pp. 182- 188.
|
[10]
|
W. Yeo and P. J. Johnson, “Diagnosis, Prevention and Management of Hepatitis B Virus Reactivation during Anticancer Therapy,” Hepatology, Vol. 43, No. 2, 2006, pp. 209-220. doi:10.1002/hep.21051
|
[11]
|
W. Yeo, P. K. S. Chan, W. M. Ho, et al. “Lamivudine for the Prevention of Hepatitis B Virus Reactivation in HBV Seropositive Cancer Patients Undergoing Cytotoxic Chemotherapy,” Journal of Clinical Oncology, Vol. 22, No. 5, 2004, pp. 927-934.
|
[12]
|
G. K. K. Lau, H. H. Y. Yiu, D. Y. T. Fong, et al., “Early is Superior to Deferred Preemptive Lamivudine Therapy for Hepatitis B Patients Undergoing Chemotherapy,” Gastrterology, Vol. 125, No. 6, 2003, pp. 1742-1749.
|